Apollomics

Focused on discovery and development of mono- and combination- oncology therapies

[Apollomics @apollomics]

Our #ClinicalTrial is now enrolling #NSCLC patients with c-Met Exon 14 mutations. If you or someone you know might be eligible, please review the details here. #cMet #Exon14 #mutation #LungCancer
https://t.co/POurWJ77YU

[Apollomics @apollomics]

Our #NACLC23 data featured the ORR of vebreltinib by gene copy number for the first time in NSCLC patients with MetExon14 skipping, demonstrating vebreltinib's potential differentiation from other cMET inhibitors.

Learn more about these promising results: https://t.co/sLapwtw2ak

[Apollomics @apollomics]

Two new cohorts added to our P2 SPARTA study, evaluating vebreltinib in #NSCLC & solid tumors with MET dysregulation - includes EGFR-mutated NSCLC patients who progress on EGFR inhibitors & histology agnostic solid tumors w. high expression of HGF & c-Met: https://t.co/l6QilYMDaN

[Apollomics @apollomics]

Exciting development from #ESMO2023: Vebreltinib’s activity in a patient with GBM with PTPRZ1-MET fusion was reported, offering hope and progress in the fight against this challenging brain cancer. #Oncology #CancerResearch #GBM https://t.co/zDoEu6OFVV

[Apollomics @apollomics]

Apollomics' partner, Avistone, has received conditional approval for vebreltinib in China, targeting MET exon 14 skipping NSCLC. This marks a significant step toward addressing needs of patients with difficult to treat cancers. Read more: https://t.co/PhRdTGhKAs

[Apollomics @apollomics]

November is #LungCancerAwarenessMonth. Did you know 1 in 16 people in the U.S. will be diagnosed in their lifetime? At #Apollomics we’re dedicated to developing new treatment options for #LungCancer patients with rare treatment resistance.

#CancerAwareness #CancerResearch

[Apollomics @apollomics]

Reminiscing on our wonderful time at the @GO2forLungCancr event at Lake Merced. A heartfelt thanks to all who joined us! Your support for patients, caregivers, survivors, and research means the world. Check out some photos from the day. #LCSM #BeatLungCancer

[Apollomics @apollomics]

September is #BloodCancerAwarenessMonth. Did you know that more than 1 million people discover they have #BloodCancer every year? At #Apollomics we’re committed to helping patients living with rare forms of #AcuteMyeloidLeukemia

#CancerAwareness #CancerResearch

[Apollomics @apollomics]

Join us at beautiful Lake Merced on September 23 to support @GO2forLungCancr! If you can't make it, any donation is appreciated to help patients, caregivers, survivors, and research. Visit our fundraising page: https://t.co/XgE0jqi7mT Hope to see you there! #LCSM #BeatLungCancer

[Apollomics @apollomics]

#WorldLungCancerDay may have been yesterday, but at Apollomics, our dedication to fighting #LungCancer continues every day. We are committed to advancing research for patients with rare and treatment-resistant lung cancers. #CancerAwareness #CancerResearch

[Apollomics @apollomics]

Glioblastoma is a devastating form of brain cancer, with few effective treatment options. Patients with rare cases of #glioblastoma face an even greater unmet need. Learn how Apollomics is advancing R&D efforts for this rare cancer here: https://t.co/mC9v0zYI6Z #CancerResearch

[Apollomics @apollomics]

Acute Myeloid Leukemia (AML) is a complex disease that requires innovative approaches to treatment. At #Apollomics, we're developing cutting-edge therapies that target the unique genetic and molecular features of #AML. Learn more here: https://t.co/iXDK1e8rgx #CancerResearch

[Apollomics @apollomics]

We believe that precision medicine and unique approaches are crucial to addressing hard-to-treat cancers. Our team is developing innovative therapies that target the underlying genetic mutations driving cancer growth. #CancerTreatment #PrecisionMedicine https://t.co/KiHtSEstUM

[Apollomics @apollomics]

Non-small cell lung cancer is the most common type of lung cancer, accounting for 85% of all cases. For those with rare treatment resistance, we're developing APL-101, a new treatment that targets c-Met, a protein involved in #NSCLC cancer resistance. https://t.co/mC9v0zZfWx

[Apollomics @apollomics]

What an incredible moment for #Apollomics! We officially rang the @Nasdaq bell. Thank you to our team, our shareholders and partners for helping us achieve this milestone and further our pursuit to develop innovative cancer treatments. $APLM #NasdaqListed

[Apollomics @apollomics]

At #Apollomics, we're dedicated to developing innovative therapies for hard-to-treat and treatment-resistant cancers. We're grateful for the opportunity to make a difference in the lives of those affected by cancer. #CancerResearch #PatientCare https://t.co/X8165hXtUN

[Apollomics @apollomics]

We are public on the @NasdaqExchange, trading under $APLM! Read more here: https://t.co/C6huWKErGe

[Apollomics @apollomics]

Big day for #Apollomics! Our merger with Maxpro Capital Acquisition Corp. is now complete, and we are officially a publicly traded company. Thank you to our team and partners who made this possible. Read the latest here: https://t.co/GKFfni0g7w

[Apollomics @apollomics]

We are thrilled to announce that Jane Wang, PhD has joined us as CSO, and will also serve as our GM in China. We look forward to her contributions to grow our global team to discover and advance new compounds into the clinic. #oncology #ClinicalResearch https://t.co/HStJfMrrNW

[Apollomics @apollomics]

Thank you to the @NFCR for allowing us to highlight the importance of #PrescisionMedicine as a method to treat certain cancers. #oncology

[National Foundation for Cancer Research @NFCR]

We are pleased to present a guest blog post by valued 2021 NFCR Annual Conference sponsor @apollomics. Its cancer drug products under development, including in clinical trials, employ precision medicine based on an individual’s unique characteristics. https://t.co/FBjLzf0kRA

[Apollomics @apollomics]

A quick reminder that we are hosting a corporate update call this week! Register here: https://t.co/lDicc5OfTL. #oncology #investorday